We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.32B
AUM Growth
-$616M
Cap. Flow
-$442M
Cap. Flow %
-13.32%
Top 10 Hldgs %
35.56%
Holding
123
New
10
Increased
41
Reduced
28
Closed
11

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$31.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$25.3M
3
GPCR icon
Structure Therapeutics
GPCR
+$24.1M
4
UNH icon
UnitedHealth
UNH
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$14.6M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$99.4M
2
PEN icon
Penumbra
PEN
+$47.9M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$44M
4
BSX icon
Boston Scientific
BSX
+$30.4M
5
IDXX icon
Idexx Laboratories
IDXX
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Staples 1.87%
3 Industrials 0.25%
4 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLT
76
DELISTED
Applied Therapeutics
APLT
$7.26M 0.22%
1,555,004
+57,086
+4% +$270K
AUPH icon
77
Aurinia Pharmaceuticals
AUPH
$2.06B
$6.74M 0.2%
1,179,740
+29,393
+3% +$155K
BPMC
78
CALL
DELISTED
Blueprint Medicines
BPMC
$6.14M 0.18%
+57,000
New +$5.71M
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$6.12M 0.18%
121,871
– –
BEAM icon
80
Beam Therapeutics
BEAM
$2.81B
$5.86M 0.18%
249,923
+102,413
+69% +$2.52M
ABOS icon
81
Acumen Pharmaceuticals
ABOS
$173M
$5.57M 0.17%
2,300,059
– –
CMPX icon
82
Compass Therapeutics
CMPX
$384M
$5.51M 0.17%
5,513,788
– –
APLS
83
DELISTED
Apellis Pharmaceuticals
APLS
$5.4M 0.16%
+140,700
New +$6.37M
FULC icon
84
Fulcrum Therapeutics
FULC
$288M
$4.51M 0.14%
727,673
– –
MGNX icon
85
MacroGenics
MGNX
$257M
$4.48M 0.13%
1,053,647
-251,603
-19% -$2.45M
MLYS icon
86
Mineralys Therapeutics
MLYS
$2.39B
$4.43M 0.13%
378,932
-413,683
-52% -$5.21M
BHVN icon
87
Biohaven
BHVN
$2.21B
$4.43M 0.13%
127,558
+574
+0.5% +$22.7K
PLRX icon
88
Pliant Therapeutics
PLRX
$65M
$4.14M 0.12%
384,996
– –
LUNG icon
89
Pulmonx
LUNG
$99.2M
$4.14M 0.12%
652,400
– –
CATX icon
90
Perspective Therapeutics
CATX
$338M
$4M 0.12%
+401,196
New +$5.8M
AUTL
91
Autolus Therapeutics
AUTL
$572M
$3.59M 0.11%
1,032,988
– –
EPIX
92
DELISTED
ESSA Pharma
EPIX
$3.56M 0.11%
677,005
– –
ACRS icon
93
Aclaris Therapeutics
ACRS
$866M
$3.03M 0.09%
2,753,495
– –
GOSS icon
94
Gossamer Bio
GOSS
$86.6M
$2.94M 0.09%
3,266,960
– –
XLO icon
95
Xilio Therapeutics
XLO
$60.8M
$2.85M 0.09%
214,519
+111,608
+108% +$1.75M
SGMT icon
96
Sagimet Biosciences
SGMT
$577M
$2.69M 0.08%
787,808
+17,137
+2% +$78.6K
GPCR icon
97
CALL
Structure Therapeutics
GPCR
$3.76B
$2.58M 0.08%
+65,600
New +$2.69M
CYPH
98
Cypherpunk Technologies Inc
CYPH
$71.9M
$2.48M 0.07%
1,266,546
+354,609
+39% +$930K
ADAP
99
DELISTED
Adaptimmune Therapeutics
ADAP
$2.36M 0.07%
2,425,468
– –
VIGL
100
DELISTED
Vigil Neuroscience
VIGL
$1.89M 0.06%
471,958
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rock Springs Capital Management held 123 positions worth $3.32B, down 16% from $3.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $442M in Q2 2024, closing 11 positions and reducing 28 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Insmed worth $54.2M.

  • Rock Springs Capital Management's largest Q2 2024 buy was Insmed: 808,356 shares worth $54.2M.
  • Rock Springs Capital Management added most to Structure Therapeutics in Q2 2024, an estimated $24.1M increase.
  • Rock Springs Capital Management's biggest Q2 2024 reduction was Immunocore, cutting an estimated $99.4M.
  • Rock Springs Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $44M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.32B portfolio in Q2 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 11 in Q2 2024.
  • Rock Springs Capital Management's portfolio value fell 16% quarter-over-quarter to $3.32B.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.